Supply of products by GlaxoSmithKline Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality and safety of therapeutic goods in Australia, aiming to protect public health by ensuring that only safe and effective therapeutic goods are available for use. The Act provides a framework for the regulation of therapeutic goods, including medicines, medical devices, and blood and blood components, and is administered by the Therapeutic Goods Administration (TGA). The 1989 Act was introduced to address the need for a comprehensive legislative framework to manage the risks associated with the use of therapeutic goods, ensuring that such goods are of acceptable quality, safety, and efficacy. The policy objective of the Act is to safeguard public health by controlling the manufacture, importation, supply, and advertising of therapeutic goods. On March 18, 2013, the delegate of the Secretary of the Department of Health and Ageing, for the purposes of subsections 14 and 14A of the Therapeutic Goods Act 1989, granted consent to GlaxoSmithKline Australia Pty Ltd for the supply of specific nadroparin calcium products that did not fully comply with certain labelling requirements under Therapeutic Goods Order No. 69. This consent was given despite the products not meeting the stipulated letter height on the syringe labels and the incomplete information about the source animal on the labels. The decision was made to ensure that the therapeutic benefits of these products could still be made available to the Australian market while the company addressed the identified compliance issues.

Scope and Application

The Therapeutic Goods Act 1989, specifically sections 14 and 14A, governs the regulation of therapeutic goods in Australia, and the legislation applies to entities and individuals involved in the supply, importation, or distribution of these goods. In this context, the Act allows the delegate of the Secretary of the Department of Health and Ageing to grant consent to a company for the supply of certain products that do not conform to specified regulatory standards, as exemplified in the notice given to GlaxoSmithKline Australia Pty Ltd. The consent allows for the supply of nadroparin calcium products under certain conditions, despite non-compliance with particular labelling requirements as outlined in Therapeutic Goods Order (TGO) 69. This Act and its application extend nationally across Australia, impacting pharmaceutical companies and medical practitioners who rely on the supply of therapeutic goods. While the Act provides for the regulation and control of therapeutic goods to ensure safety and efficacy, it also includes provisions for exemptions or special consents, as demonstrated by this specific case of non-conforming products. The geographic reach of the Act is nationwide, and it applies to all entities and individuals within the Commonwealth of Australia involved in the therapeutic goods supply chain.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") governs the regulation of therapeutic goods in Australia. Under section 14 of the Act, the delegate of the Secretary of the Department of Health and Ageing can give consent for certain products to be supplied, even if they do not fully comply with the Therapeutic Goods Orders (TGOs). Specifically, the Act allows for the supply of products that do not meet certain labelling requirements if the delegate deems it necessary in the interest of public health. In this case, section 14A consent was given for GlaxoSmithKline Australia Pty Ltd to supply specified nadroparin calcium injection syringes that do not fully conform with TGO 69 regarding label specifications. The obligations imposed by this legislation on the parties involved include ensuring that the products supplied meet the minimum standards necessary for safe and effective use, despite the non-compliance with specific labelling requirements. The company must adhere to all other relevant provisions of the Act and any applicable TGOs, ensuring that the therapeutic goods are of acceptable quality and safe for their intended use. This includes maintaining proper records and documentation to demonstrate compliance with the Act and any consents granted. Breaches of the Therapeutic Goods Act 1989 and associated TGOs can result in both civil and criminal penalties. Civil penalties may include fines and legal actions for non-compliance, while criminal penalties can lead to imprisonment and fines. The maximum penalties for offences under the Act depend on the severity of the breach and can vary significantly. For instance, supplying goods that do not comply with regulatory standards can result in fines of up to $2,200,000 for a corporation and imprisonment for up to five years for an individual. These provisions ensure that the integrity of the therapeutic goods market is maintained and that public health is protected from unsafe or substandard products.